At the National Healthcare Security Administration (NHSA)’s request, the NHSA Drug Pricing and Procurement Guidance Center compiled, as of April 1, 2026, a list of more than 200 pharmaceutical companies rated “seriously untrustworthy” or “particularly seriously untrustworthy” in price and procurement. The price‑procurement credit ratings are based primarily on bribery amounts, improper pricing behavior and disruption of centralized procurement order. NHSA thresholds for cumulative bribery: ≥10,0

At the National Healthcare Security Administration (NHSA)’s request, the NHSA Drug Pricing and Procurement Guidance Center compiled, as of April 1, 2026, a list of more than 200 pharmaceutical companies rated “seriously untrustworthy” or “particularly seriously untrustworthy” in price and procurement. The price‑procurement credit ratings are based primarily on bribery amounts, improper pricing behavior and disruption of centralized procurement order. NHSA thresholds for cumulative bribery: ≥10,000 yuan = untrustworthy; ≥500,000 yuan = seriously untrustworthy; ≥1,000,000 yuan = particularly seriously untrustworthy.